Release of EpiTox
EpiTox – completing our ValidaTe platform for TCR-mimic antibody development
12.12.2025
Following our EpiPredict publication (click to read the publication), we’re pleased to announce the pre-print release of EpiTox – completing our Validate platform for TCR-mimic antibody development.
As outlined in our EpiPredict paper, EpiTox is a machine-learning–powered platform for peptide-centric pHLA off-target risk assessment, addressing a critical safety challenge in TCR-mimic (TCRm) antibody development.
Using MAGE-A3 as a case study, we demonstrate how EpiTox identifies sequence-related, high-risk off-target peptides. Importantly, applying EpiTox to an anti–MAGE-A3 TCRm antibody revealed previously unrecognized off-targets, underscoring its value for early, mechanism-driven safety de-risking and robust candidate selection in pre-clinical development.
With the publication of EpiTox, all three components of our ValidaTe platform are now publicly validated and available:
- SCORE: proprietary high-throughput pHLA screening
(Link to paper) - EpiPredict: TCRm-centric, proteome-wide off-target identification
(Link to paper) - EpiTox: peptide-centric pHLA off-target risk assessment (Link to paper)
Looking ahead: Updates on our MAGE-A4 lead molecules are planned for Q1 2026.